m.- I'm also still holding a rather large bag of RNA. Two questions, for you or anyone else interested:
1. While their PR yesterday said that they regained the rights to disapersen, I think that the FierceBiotech headline more accurately captures the reality of the situation: "GSK dumps a failed muscular dystrophy drug back in Prosensa's lap."
Since their pipeline is far from empty, why not simply admit that disapersen didn't work out, and move on?
2. More generally, just musing, it seems to me that biotechs can get too attached to a failed drug, almost in a weirdly personal way, and can't let them go. I realize that an enormous amount of time and money is spent in R&D, but the drug is not your child-it’s a cold hard business decision-stop pouring good money after bad.
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius
